ASCO 2024: Zanzalintinib (XL092) plus Nivolumab in Non-Clear Cell Renal Cell Carcinoma: The Randomized Phase 3 STELLAR-...
(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL was host to a kidney and bladder cancers trials-in-progress poster session. Dr. Sumanta Pal presented the results of the randomized phase III STELLAR- …